Abstract
1 Disposition of oral brotizolam (0.5 mg) was studied in male patients with liver cirrhosis (patients) and in other patients (control) matched for age, weight, smoking and drinking habits.
2 Absorption of brotizolam was relatively rapid in both groups with a median peak time (range) of 1.0 (0.5-2.0) h. Peak concentrations were also similar with median values of 7.1 (3.2-10.7) ng/ml in patients and 9.4 (2.9-19.0 ng/ml) in controls.
3 Elimination half-life was longer in patients than in controls. The median values were 12.8 (9.4-25) h and 6.9 (4.4-8.4) h respectively (P < 0.01). In two patients hardly any drug elimination was observed, indicating severe impairment of drug metabolizing activity. The prolongation of the elimination half-life was likely to be due to a decrease in clearance (45 ml/min in patients compared with 64 ml/min in controls), and an increase in volume of distribution (0.62 l/kg and 0.39 l/kg respectively).
4 Median values of protein unbound fraction of brotizolam were 9.2 (7.8-10.4)% in controls and 12.4 (10.4-18.9)% in patients. Clearance of unbound drug was 612 ml/min and 380 ml/min respectively.
Keywords: brotizolam, pharmacokinetics, cirrhosis
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Breimer D. D., Zilly W., Richter E. Influence of corticosteroid on hexobarbital and tolbutamide disposition. Clin Pharmacol Ther. 1978 Aug;24(2):208–212. doi: 10.1002/cpt1978242208. [DOI] [PubMed] [Google Scholar]
- Closson R. G. Terminal half-lives of drugs studied in patients with hepatic diseases. Am J Hosp Pharm. 1977 May;34(5):520–524. [PubMed] [Google Scholar]
- Jochemsen R., Nandi K. L., Corless D., Wesselman J. G., Breimer D. D. Pharmacokinetics of brotizolam in the elderly. Br J Clin Pharmacol. 1983;16 (Suppl 2):299S–307S. doi: 10.1111/j.1365-2125.1983.tb02304.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jochemsen R., Van Beusekom B. R., Spoelstra P., Janssens A. R., Breimer D. D. Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. Br J Clin Pharmacol. 1983 Mar;15(3):295–302. doi: 10.1111/j.1365-2125.1983.tb01502.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jochemsen R., Wesselman J. G., Hermans J., van Boxtel C. J., Breimer D. D. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. Br J Clin Pharmacol. 1983;16 (Suppl 2):285S–290S. doi: 10.1111/j.1365-2125.1983.tb02302.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Klotz U., Avant G. R., Hoyumpa A., Schenker S., Wilkinson G. R. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975 Feb;55(2):347–359. doi: 10.1172/JCI107938. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kraus J. W., Desmond P. V., Marshall J. P., Johnson R. F., Schenker S., Wilkinson G. R. Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther. 1978 Oct;24(4):411–419. doi: 10.1002/cpt1978244411. [DOI] [PubMed] [Google Scholar]
- Roberts R. K., Wilkinson G. R., Branch R. A., Schenker S. Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Gastroenterology. 1978 Sep;75(3):479–485. [PubMed] [Google Scholar]
- Sellers E. M., Greenblatt D. J., Giles H. G., Naranjo C. A., Kaplan H., MacLeod S. M. Chlordiazepoxide and oxazepam disposition in cirrhosis. Clin Pharmacol Ther. 1979 Aug;26(2):240–246. doi: 10.1002/cpt1979262240. [DOI] [PubMed] [Google Scholar]
- Shull H. J., Wilkinson G. R., Johnson R., Schenker S. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med. 1976 Apr;84(4):420–425. doi: 10.7326/0003-4819-84-4-420. [DOI] [PubMed] [Google Scholar]
- Wilkinson G. R., Schenker S. Effects of liver disease on drug disposition in man. Biochem Pharmacol. 1976 Dec 15;25(24):2675–2681. doi: 10.1016/0006-2952(76)90256-2. [DOI] [PubMed] [Google Scholar]